Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase Ib and II open-label, multi-center study to evaluate the safety, tolerability, pharmacodynamics, and antitumor activity of MEDI4736 in combination with chemotherapy or AZD5069 in patients with pancreatic ductal adenocarcinoma (PDAC). This study will consist of 2 independent cohorts. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04935359 -
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
|
Phase 3 | |
| Active, not recruiting |
NCT05095064 -
Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
|
||
| Active, not recruiting |
NCT05039177 -
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04888312 -
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT04390763 -
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
|
Phase 2 | |
| Not yet recruiting |
NCT06206876 -
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
|
Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Completed |
NCT02501902 -
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
|
Phase 1 | |
| Active, not recruiting |
NCT04581343 -
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients
|
Phase 1 | |
| Completed |
NCT02558894 -
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
|
Phase 2 | |
| Terminated |
NCT02732938 -
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
|
Phase 2 | |
| Recruiting |
NCT05472259 -
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
|
Phase 2 | |
| Recruiting |
NCT06445062 -
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02600949 -
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT05630183 -
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT04329949 -
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
| Terminated |
NCT02101021 -
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
| Suspended |
NCT05685602 -
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06398587 -
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT04990037 -
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 1 |